在来那度胺和利妥昔单抗基础上加用维奈克拉治疗初治套细胞淋巴瘤安全有效
这项多中心、开放标签、非随机、单臂研究纳入28例未选择的初治套细胞淋巴瘤患者,来那度胺20 mg每日第1-21天(28天周期),维奈克拉经时间-事件持续重评估法确定剂量,利妥昔单抗375 mg/m2每周自第1周期第1天至第2周期第1天。未观察到剂量限制性毒性,所有患者接受维奈克拉最大耐受剂量400 mg每日;总缓解率和完全缓解率分别为96%和86%,86%患者通过下一代测序达到微小残留病不可检测,中位总生存和无进展生存均未达到。
要点
- 维奈克拉联合来那度胺和利妥昔单抗在初治套细胞淋巴瘤中未观察到剂量限制性毒性。
- 所有患者接受维奈克拉最大耐受剂量400 mg每日。
- 总缓解率96%,完全缓解率86%,86%患者达到微小残留病不可检测。
核心结论
- 来那度胺、利妥昔单抗和维奈克拉联合方案在初治套细胞淋巴瘤患者中安全有效。
研究设计与样本
- 多中心、开放标签、非随机、单臂研究,纳入28例未选择的初治套细胞淋巴瘤患者,不论年龄、体能状态或危险因素。
主要发现
- 未观察到剂量限制性毒性,所有患者接受维奈克拉最大耐受剂量400 mg每日。
- 最常见不良事件为中性粒细胞减少和血小板减少。
- 总缓解率和完全缓解率分别为96%和86%。
- 86%患者通过下一代测序达到微小残留病不可检测。
- 中位总生存和无进展生存均未达到。
关键数值与推荐
- 来那度胺剂量为20 mg每日,每28天周期第1至21天给药。
- 维奈克拉剂量通过时间-事件持续重评估法确定,最大耐受剂量为400 mg每日。
- 利妥昔单抗剂量为375 mg/m2每周,自第1周期第1天开始至第2周期第1天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a rare, incurable hematological malignancy with a heterogeneous presentation and clinical course. A wide variety of chemotherapy-based regimens are currently used in patients who are untreated. Over the last several years, several targeted or small-molecule therapies have shown efficacy in the relapsed/refractory setting and have since been explored in the frontline setting. Lenalidomide plus rituximab was explored in a phase 2 study of 38 patients with MCL who were untreated and ineligible to receive transplantation, in which the combination produced durable remissions. We looked to build upon this regimen by adding venetoclax to the combination. We conducted a multicenter, open-label, nonrandomized, single-arm study to evaluate this combination. We enrolled 28 unselected patients with untreated disease irrespective of age, fitness, or risk factors. Lenalidomide was dosed at 20 mg daily from days 1 to 21 of each 28-day cycle. The dose of venetoclax was determined using the time-to-event continual reassessment method. Rituximab was dosed at 375 mg/m2 weekly, starting on cycle 1, day 1 until cycle 2, day 1. No dose-limiting toxicities were noted. All patients were treated with venetoclax at the maximum tolerated dose of 400 mg daily. The most common adverse events were neutropenia and thrombocytopenia. The overall and complete response rates were 96% and 86%, respectively. In total, 86% of patients achieved minimal residual disease undetectability via next-generation sequencing. The median overall and progression-free survivals were not reached. The combination of lenalidomide, rituximab, and venetoclax is a safe and effective regimen in patients with untreated MCL. This trial was registered at www.clinicaltrials.gov as #NCT03523975.
引用
- Phillips TJ, Bond D, Takiar R, et al. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. 2023. PMID: 37013954. doi:10.1182/bloodadvances.2023009992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。